Table 1

Patient demographics and clinical characteristics by HIC classification (n=877)

Total
(n=877)
HIC-hot
(n=622, 70.9%)
HIC-cold
(n=255, 29.1%)
P value
Age
 Mean (SD)68.0 (10.2)68.4 (10.3)67.0 (10.0)0.070
 Median (range)67.6 (35.2–95.1)68.1 (35.2–92.9)66.5 (36.5–95.1)0.075
Gender, n (%)0.004
 Female382 (43.6)290 (46.6)92 (36.1)
 Male495 (56.4)332 (53.4)163 (63.9)
Histology, n (%)<0.001
 Adenocarcinoma573 (65.3)430 (69.1)143 (56.1)
 Squamous188 (21.4)116 (18.6)72 (28.2)
 NSCLC other116 (13.2)76 (12.2)40 (15.7)
Disease stage at study entry, n (%)0.739
 Stage IIIB112 (12.8)78 (12.5)34 (13.3)
 Stage IV765 (87.2)544 (87.5)221 (86.7)
ECOG status at study entry, n (%)<0.001
 PS 0222 (25.3)184 (29.6)38 (14.9)
 PS 1432 (49.3)299 (48.1)133 (52.2)
 PS 2183 (20.9)117 (18.8)66 (25.9)
 PS 335 (4.0)22 (3.5)13 (5.1)
 PS 45 (0.6)0 (0.0)5 (2.0)
Smoking status, n (%)0.056
 Current smoker332 (37.9)230 (37.0)102 (40.0)
 Former smoker441 (50.3)308 (49.5)133 (52.2)
 Never smoker104 (11.9)84 (13.5)20 (7.8)
PD-L1 expression, n (%)0.632
 High (≥50%)168 (19.2)119 (19.1)49 (19.2)
 Low (≥1% and <50%)137 (15.6)100 (16.1)37 (14.5)
 Negative (<1%)169 (19.3)125 (20.1)44 (17.3)
 NA403 (46.0)278 (44.7)125 (49.0)
Disease status at study entry, n (%)<0.001
 Newly diagnosed820 (93.5)571 (91.8)249 (97.6)
 Recurrent55 (6.3)50 (8.0)5 (2.0)
 Other2 (0.2)1 (0.2)1 (0.4)
Treatment regimen, n (%)0.026
 ICI monotherapy117 (13.3)80 (12.9)37 (14.5)
 ICI+ chemotherapy161 (18.4)113 (18.2)48 (18.8)
 ICI other combination6 (0.7)3 (0.5)3 (1.2)
 Pt-based chemotherapy392 (44.7)284 (45.7)108 (42.4)
 Other chemotherapy19 (2.2)13 (2.1)6 (2.4)
 TKI40 (4.6)35 (5.6)5 (2.0)
 Radiation32 (3.6)25 (4.0)7 (2.7)
 Other active treatment16 (1.8)14 (2.3)2 (0.8)
 No active treatment94 (10.7)55 (8.8)39 (15.3)
  • ECOG, Eastern Cooperative Oncology Group; HIC, host immune classifier; ICI, immune checkpoint inhibition; NA, not available; NSCLC, non-small cell lung cancer; PD-L1, programmed death ligand 1; PS, performance status; Pt, platinum; TKI, tyrosine kinase inhibitor.